Vardenafil
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Vardenafil: From Unspecified Original Indication to Amenorrhea
One-Sentence Summary
Vardenafil’s original approved indication is not specified in this Evidence Pack (a confirmed data gap), though the accompanying rationale text characterizes it as a phosphodiesterase type 5 (PDE5) inhibitor acting on the vascular smooth muscle cGMP pathway. The TxGNN model predicts a possible new application in Amenorrhea, but this prediction is currently supported by 0 clinical trials and 0 publications, and the evidence pack’s own mechanistic analysis explicitly found no known biological link between PDE5 inhibition and the pathways that govern amenorrhea.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in Evidence Pack (data gap) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 98.37% |
| Evidence Level | L5 |
| EU Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for vardenafil is not available in this Evidence Pack (flagged internally as data gap DG002, High severity). Based on the rationale text accompanying this prediction, vardenafil is classified as a phosphodiesterase type 5 (PDE5) inhibitor — a drug class that acts on the vascular smooth muscle cGMP signalling pathway.
No information on vardenafil’s original approved indication is included in this Evidence Pack, and no marketing authorizations are recorded for the target market (0 licenses, status: Not Marketed). This significantly limits any comparison between the original clinical use and the newly predicted indication.
Importantly, the evidence pack’s own mechanistic assessment explicitly states that there is no known direct connection between the PDE5/cGMP vascular smooth-muscle pathway and the hypothalamic-pituitary-ovarian axis mechanisms that regulate menstruation, and no supporting literature was identified for this pairing. This indicates the prediction is driven purely by the TxGNN knowledge-graph model’s statistical pattern-matching, without an established or currently plausible biological rationale.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
EU Market Information
Vardenafil currently holds no marketing authorizations within the scope of this Evidence Pack (market status: Not Marketed; 0 authorizations recorded).
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This is an L5 (AI-prediction-only) candidate with zero clinical trials, zero supporting literature, and an explicit statement in the evidence pack’s own mechanistic rationale that no known biological link exists between PDE5 inhibition and amenorrhea. There is currently no basis to advance this candidate beyond hypothesis generation.
To proceed, the following is needed:
- Vardenafil’s official mechanism of action (query DrugBank API — resolves data gap DG002)
- Regulatory label warnings and contraindications (download and parse the official product label — resolves data gap DG001, blocking for safety pre-screening)
- Original approved indication and licensing data for the target market
- Independent literature or preclinical mechanistic studies specifically linking PDE5 inhibition to hypothalamic-pituitary-ovarian axis physiology, before this candidate can move past hypothesis stage
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.